新型冠狀病毒疫苗與癲癇相關研究進展_Journal of Epilepsy

Authors：

劉家琪 ^1,2,3 , 楊逸昊 ^1,2 , 王勝 ^1,2 , 童婧怡 ^1,2 , 馬琳 ^1,2 , 蔡毅 ^1,2 ,  李其富 ^1,2,3

1. ;
2. ;
3. ;

Corresponding?author：

李其富, Email: lee-chief@163.com

Keywords：

新型冠狀病毒疫苗; 癲癇; 研究進展

DOI：

10.7507/2096-0247.20210053

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

新型冠狀病毒肺炎（Coronavirus disease 2019，COVID-19）目前仍在世界范圍內呈現大流行的趨勢，隨著病毒的肆意蔓延及迅速變異，針對新冠病毒的疫苗研發工作也在不斷深入。癲癇患者作為新冠疫苗的慎用人群，其適用條件的探究也在隨著患者需求的增加而日漸清晰。目前已有相關指南對癲癇患者能否接種新冠疫苗給出初步建議，但針對患者個體情況的具體應用條件尚未明確。現有研究表明，目前已上市投入使用的疫苗中，接種后的神經系統不良反應雖存在，但癲癇患者并非疫苗接種的絕對禁忌人群。本文主要就新型冠狀病毒疫苗針對癲癇患者的具體適用條件及相關建議作一綜述。

Citation： 劉家琪, 楊逸昊, 王勝, 童婧怡, 馬琳, 蔡毅, 李其富. 新型冠狀病毒疫苗與癲癇相關研究進展. Journal of Epilepsy, 2021, 7(4): 327-334. doi: 10.7507/2096-0247.20210053 Copy

1.	Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and haemophilus influenzae type b. JAMA, 2012, 307(8): 823-831.
2.	Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021, 21(2): 181-192.
3.	Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2020, 396(10249): 479-488.
4.	Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med, 2020, 383(24): 2320-2332.
5.	Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med, 2020, 383(27): 2603-2615.
6.	Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis, 2021, 21(5): 637-646.
7.	Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Disease, 2021, S1473-3099(21): 00070-0.
8.	Voysey Merryn et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 2020, 397(10269): 99-111.
9.	Chu Laurence et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine, 2021, 39(20): 2791-2799.
10.	Doroftei Bogdan et al. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics, 2021, 11(4): 579.
11.	Logunov Denis Y et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 2021, 397(10275): 671-681.
12.	Xia Shengli et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA, 2020, 324(10): 951-960.
13.	Sadoff Jerald et al. Interim results of a phase 1–2a trial of Ad26. COV2. S Covid-19 vaccine. New England Journal of Medicine, 2021, 384(19): 1824-1835.
14.	Xiang Wang. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 2021, 384(16): 1576-1578.
15.	中國抗癲癇協會. 臨床診療指南癲癇病分冊(2015修訂版)[M]. 北京: 人民衛生出版社, 2015: 15-16.
16.	Deng L, Wood N, Danchin M. Seizures following vaccination in children: Risks, outcomes and management of subsequent revaccination. Aust J Gen Pract, 2020, 49(10): 644-649.
17.	葉盛. 特殊健康狀態兒童預防接種專家共識之八——癲癇與預防接種. 中國實用兒科雜志, 2019, 34(02): 82-84.
18.	Reyes IS, Hsieh DT, Laux LC, et al. Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome. Pediatrics, 2011, 128(3): e699-702.

1. Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and haemophilus influenzae type b. JAMA, 2012, 307(8): 823-831.
2. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021, 21(2): 181-192.
3. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2020, 396(10249): 479-488.
4. Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med, 2020, 383(24): 2320-2332.
5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med, 2020, 383(27): 2603-2615.
6. Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis, 2021, 21(5): 637-646.
7. Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Disease, 2021, S1473-3099(21): 00070-0.
8. Voysey Merryn et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 2020, 397(10269): 99-111.
9. Chu Laurence et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine, 2021, 39(20): 2791-2799.
10. Doroftei Bogdan et al. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics, 2021, 11(4): 579.
11. Logunov Denis Y et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 2021, 397(10275): 671-681.
12. Xia Shengli et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA, 2020, 324(10): 951-960.
13. Sadoff Jerald et al. Interim results of a phase 1–2a trial of Ad26. COV2. S Covid-19 vaccine. New England Journal of Medicine, 2021, 384(19): 1824-1835.
14. Xiang Wang. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 2021, 384(16): 1576-1578.
15. 中國抗癲癇協會. 臨床診療指南癲癇病分冊(2015修訂版)[M]. 北京: 人民衛生出版社, 2015: 15-16.
16. Deng L, Wood N, Danchin M. Seizures following vaccination in children: Risks, outcomes and management of subsequent revaccination. Aust J Gen Pract, 2020, 49(10): 644-649.
17. 葉盛. 特殊健康狀態兒童預防接種專家共識之八——癲癇與預防接種. 中國實用兒科雜志, 2019, 34(02): 82-84.
18. Reyes IS, Hsieh DT, Laux LC, et al. Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome. Pediatrics, 2011, 128(3): e699-702.

Previous Article
癲癇患者與新型冠狀病毒肺炎疫苗：專家建議
Next Article
兒童良性癲癇伴中央顳區棘波的研究進展

Journal of Epilepsy

新型冠狀病毒疫苗與癲癇相關研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content